Characterization of the T cell recognition of hepatitis B surface antigen (HBsAg) by good and poor responders to hepatitis B vaccines

Clinical and Experimental Immunology

Volumn 122, Issue 3, 2000, Pages 390-399

  Desombere, I ^a   Gijbels, Y ^a   Verwulgen, A ^a   Leroux Roels, G ^a,b  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

HBsAg; HLA restriction; Synthetic peptides; T cell epitopes

Indexed keywords

HEPATITIS B VACCINE; HLA ANTIGEN CLASS 2;

ANTIGEN BINDING; ANTIGEN RECOGNITION; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; HEPATITIS B VIRUS; HLA SYSTEM; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOPHENOTYPING; PRIORITY JOURNAL; VACCINATION;

ADULT; AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; ANTIGENS, CD3; ANTIGENS, CD4; CELL LINE; EPITOPES, T-LYMPHOCYTE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HLA-DP ANTIGENS; HLA-DQ ANTIGENS; HLA-DR ANTIGENS; HUMANS; MOLECULAR SEQUENCE DATA; PEPTIDES; T-LYMPHOCYTES, HELPER-INDUCER; VACCINES, SYNTHETIC;

EID: 0034528135     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2000.01383.x     Document Type: Article

References (59)

1. Hepatitis B virus immunopathogenesis
2. Immune response to the hepatitis B virus: Infection, animal models, vaccination
3. Hepatitis B vaccine: Demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States
4. T-cell dependence of immune response to hepatitis B surface antigen in mice
5. In vitro response to HBsAg of peripheral blood lymphocytes from vaccine recipients of hepatitis B vaccine
6. Correlation between in vivo humoral and in vitro cellular immune responses following immunization with hepatitis B surface antigen (HBsAg) vaccines
7. In vitro immune responses to hepatitis B surface antigens S and preS2 during acute infection by hepatitis B virus in humans
8. Successful postexposure vaccination against hepatitis B in chimpanzees
9. Large surface proteins of hepatitis B virus containing the preS sequence
10. Binding of immunogenic peptides to Ia histocompatibility molecules
11. The relation between major histocompatibility complex (MHC) restriction and the capacity of Ia to bind immunogenic peptides
12. Genetic regulation of the immune response to hepatitis B surface antigen (HBsAg). IV. Distinct H-2-linked Ir genes control antibody responses to different HBsAg determinants on the same molecule and map to the I-A and I-C sub-regions
13. Recognition of hepatitis B surface antigen by human T lymphocytes: Proliferative and cytotoxic responses to a major antigenic determinant defined by synthetic peptides
14. Fine specificity of the human T-cell response to the hepatitis B virus preS1 antigen
15. Presentation of an immunodominant T-cell epitope of hepatitis B surface antigen by the HLA-DPw4 molecule
16. A synthetic peptide spontaneously self-assembles to reconstruct a group-specific, conformational determinant of hepatitis B surface antigen
17. Human T-helper cell responses to a synthetic peptide derived from the hepatitis B surface antigen
18. Immunity to hepatitis B: Analysis of antibody and cellular responses in recipients of a plasma-derived vaccine using synthetic peptides mimicking S and preS regions
19. Identification of an epitope for T cells correlated with antibody response to hepatitis B surface antigen in vaccinated humans
20. + T lymphocyte clones induced by vaccination with rHBsAg vaccine
21. Cellular recognition and HLA restriction of a midsequence HBsAg peptide in hepatitis B vaccinated individuals
22. Nonresponse to hepatitis B vaccines and the kinetics of anti-HBs production
23. Unresolved issues in hepatitis B immunization
24. Prevention and therapy of viral hepatitis
25. Human leukocyte antigens influence the immune response to a pre-S/S hepatitis B vaccine
26. The influence of host factors and immunogenetics on lymphocyte responses to Hepagene vaccination
27. Cellular and humoral immune responses induced by intradermal or intramuscular vaccination with the major hepatitis B surface antigen
28. Genetics of anti-HBs responsiveness: I. HLA DR7 and nonresponsiveness to hepatitis vaccination
29. Humoral immune response after hepatitis-B-vaccination: Kinetics of anti-HBs antibodies and demonstration of HLA antigens
30. Nonresponsiveness to hepatitis B vaccine in health care workers. Results of revaccination and genetic typings
31. Response to hepatitis B vaccine: Multiple HLA-genes are involved
32. Genetic prediction of nonresponse to hepatitis B vaccine
33. Nonresponders to hepatitis B vaccine can present envelope particles to T lymphocytes
34. Hepatitis B vaccine containing surface antigen and selected preS1 and preS2 sequences. 2. Immunogenicity in poor responders to hepatitis B vaccines
35. Summary of clinical findings on Engerix-B, a genetically engineered yeast derived hepatitis B vaccine
36. A new hepatitis B vaccine containing preS1 and preS2 epitopes from S. cerevisiae
37. Hepatitis B vaccine containing surface antigen and selected preS1 and preS2 sequences. 1. Safety and immunogenicity in young, healthy adults
38. Responses to hepatitis B vaccine in a young adult population
39. Rapid DNA typing of class II HLA antigens using the polymerase chain reaction and reverse dot blot hybridization
40. Nomenclature for factors of the HLA system, 1996
41. Solid phase synthesis
42. Limiting dilution analysis of the cells of immune system I. The clonal basis of the immune response
43. A topological model for hepatitis B surface antigen
44. The preS1 antigen of hepatitis B virus is highly immunogenic at the T cell level in man
45. Cellular response and anti-HBs synthesis in vitro after vaccination with yeast-derived recombinant hepatitis vaccine
46. Deficient T-cell responses in non-responders to hepatitis B vaccination: Absence of Th1 cytokine production
47. + surface phenotype and a T helper type 1 profile of cytokine secretion in the liver of patients chronically infected with hepatitis B virus
48. Genetic regulation of the immune response to hepatitis B surface antigen (HBsAg) VI. T cell fine specificity
49. Self-peptide released from class II HLA-DR1 exhibits a hydrophobic two-residue contact motif
50. Pool sequencing of natural HLA-DR, DQ, and DP ligands reveals detailed peptide motifs, constraints of processing, and general rules
51. Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles
52. MHC ligands and peptide motifs: First listing
53. Characterization of a conserved T cell epitope in HIV-1 gp41 recognized by vaccine-induced human cytolytic T cells
54. Normal HBsAg presentation and T-cell defect in the immune response of nonresponders
55. The cellular basis for lack of antibody response to hepatitis B vaccine in humans
56. Contribution of human leukocyte antigens to the antibody response to hepatitis B vaccination
57. Identification of a putative motif for binding of peptides to HLA-DQ2
58. The peptide binding motif of the disease associated HLA-DQ (alpha 1*0501, beta 1*0201) molecule
59. Identification of an HLA-DQ2 peptide binding motif and HLA-DPw3-bound self-peptide by pool sequencing